论文部分内容阅读
目的：探讨尿激酶型纤溶酶原激活剂（ｕＰＡ）与膀胱肿瘤恶性程度及浸润深度之间的关系。方法：采用酶联免疫吸附实验（ＥＬＩＳＡ）检测５１例膀胱移行细胞癌病人术前、术后静脉血及肿瘤组织ｕＰＡ含量。结果：Ｇ３级肿瘤组织ｕＰＡ含量明显高于Ｇ１和Ｇ２级（Ｐ均＜０．０１），Ｇ１与Ｇ２间的ｕＰＡ无显著性差异；浸润癌肿瘤组织ｕＰＡ含量明显高于表浅肿瘤组织（Ｐ＜０．０５）。病人术前及术后静脉血ｕＰＡ含量与正常人静脉血ｕＰＡ含量无显著性差异。结论：肿瘤组织ｕＰＡ含量可以反映膀胱肿瘤的恶性程度和肿瘤浸润深度
Objective: To investigate the relationship between urokinase-type plasminogen activator (uPA) and the degree of malignancy and invasive depth of bladder cancer. Methods: Enzyme-linked immunosorbent assay (ELISA) was used to detect uPA levels in 51 cases of bladder transitional cell carcinoma before and after operation. Results: The level of uPA in G3 tumors was significantly higher than that in G1 and G2 (P<0.01). There was no significant difference in uPA between G1 and G2. The content of uPA in infiltrating tumor tissue was significantly higher than that in superficial tumors (P). <0.05). There was no significant difference in uPA between venous blood before and after surgery and uPA in normal people. Conclusion: The tumor tissue uPA content can reflect the degree of malignancy and tumor invasion depth of bladder tumors